Kimia Biosciences Ltd
Incorporated in 1993, Kimia Biosciences Ltd
is in the business of Pharmaceutical products[1]
- Market Cap ₹ 238 Cr.
- Current Price ₹ 50.2
- High / Low ₹ 58.4 / 32.0
- Stock P/E
- Book Value ₹ 0.08
- Dividend Yield 0.00 %
- ROCE -12.4 %
- ROE -81.6 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 626 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 10.9% over past five years.
- Company has a low return on equity of -16.5% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9 | 12 | 6 | 2 | 0 | 1 | 76 | 94 | 106 | 133 | 125 | 129 | 97 | |
8 | 10 | 7 | 4 | 4 | 2 | 74 | 88 | 102 | 124 | 124 | 133 | 107 | |
Operating Profit | 1 | 2 | -0 | -2 | -3 | -1 | 2 | 6 | 4 | 8 | 1 | -5 | -10 |
OPM % | 12% | 16% | -5% | -110% | -1,779% | -56% | 3% | 6% | 4% | 6% | 0% | -4% | -10% |
0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | |
Interest | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 3 | 3 | 4 | 4 | 5 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 3 |
Profit before tax | 0 | 1 | -1 | -2 | -4 | -1 | 2 | 4 | 1 | 6 | -5 | -12 | -18 |
Tax % | 11% | 6% | 1% | -1% | -0% | 8% | -4% | -1% | -13% | 8% | 26% | 25% | |
0 | 1 | -1 | -2 | -4 | -1 | 2 | 4 | 1 | 5 | -4 | -9 | -13 | |
EPS in Rs | 0.54 | 1.71 | -1.06 | -2.30 | -5.48 | -1.26 | 2.26 | 2.64 | 0.30 | 1.08 | -0.78 | -1.98 | -2.80 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 27% |
5 Years: | 11% |
3 Years: | 7% |
TTM: | -28% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -166% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 5% |
1 Year: | 44% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -3% |
3 Years: | -17% |
Last Year: | -82% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 1 | 1 | 5 | 5 | 5 | 5 | 5 |
Reserves | -6 | -5 | -6 | -7 | -11 | -12 | -2 | 2 | 9 | 14 | 10 | 1 | -4 |
Preference Capital | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | |
2 | 1 | 0 | 1 | 7 | 14 | 33 | 31 | 34 | 45 | 41 | 53 | 52 | |
3 | 2 | 3 | 4 | 1 | 3 | 25 | 31 | 38 | 43 | 54 | 63 | 50 | |
Total Liabilities | 7 | 6 | 6 | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 102 |
3 | 4 | 4 | 3 | 3 | 7 | 13 | 16 | 18 | 28 | 35 | 34 | 33 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 2 | 6 | 6 | 0 | 1 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3 | 2 | 2 | 1 | 1 | 2 | 43 | 48 | 62 | 72 | 74 | 87 | 69 | |
Total Assets | 7 | 6 | 6 | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 102 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | 1 | 1 | 0 | -6 | -1 | -7 | -3 | 0 | 6 | 8 | -7 | |
-1 | -1 | -0 | 0 | -0 | -6 | -2 | -2 | -9 | -14 | -1 | -3 | |
-1 | -1 | -0 | -0 | 6 | 7 | 10 | 4 | 8 | 8 | -8 | 10 | |
Net Cash Flow | 0 | -0 | -0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 80 | 41 | 22 | 56 | 173 | 20 | 141 | 113 | 128 | 115 | 88 | 87 |
Inventory Days | 75 | 50 | 319 | 615 | 59 | 83 | 92 | 89 | 146 | 183 | ||
Days Payable | 988 | 667 | 91 | 511 | 120 | 91 | 121 | 116 | 159 | 177 | ||
Cash Conversion Cycle | 80 | 41 | -891 | -560 | 401 | 124 | 80 | 105 | 100 | 88 | 76 | 93 |
Working Capital Days | -50 | -10 | -58 | -530 | -173 | -1,358 | 70 | 83 | 94 | 98 | 78 | 79 |
ROCE % | 22% | 46% | -25% | -127% | -188% | -10% | 10% | 17% | 9% | 16% | -2% | -12% |
Documents
Announcements
- Compliance Certificate Pursuant To Regulation 40(9) Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015. 19 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 18 Apr
- Certificate Under Regulation 7(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015. 10 Apr
- Intimation Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For Written Confirmation For Active Substances Imported Into The European Union (EU) For Medical Products For Human Use. 10 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Dear Sir/ Madam, Pursuant to Regulation 74(5) of SEBI ( Depositories and Participants) Regulations, 2018, please find enclosed a copy of the certificate for the …
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Profile:[1][2]
Company manufactures Active Pharmaceuticals Ingredients. It has commercialized 25+ products with 9-10 molecules under development